Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 87 条

[11] Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Cho, Shih-Feng
Anderson, Kenneth C.
Tai, Yu-Tzu
[J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
[12] Costa LJ, 2019, J CLIN ONCOL, V37
[13] The significance of OX40 and OX40L to T-cell biology and immune disease
Croft, Michael
So, Takanori
Duan, Wei
Soroosh, Pejman
[J]. IMMUNOLOGICAL REVIEWS, 2009, 229 : 173 - 191
[14] OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
Curti, Brendan D.
Kovacsovics-Bankowski, Magdalena
Morris, Nicholas
Walker, Edwin
Chisholm, Lana
Floyd, Kevin
Walker, Joshua
Gonzalez, Iliana
Meeuwsen, Tanisha
Fox, Bernard A.
Moudgil, Tarsem
Miller, William
Haley, Daniel
Coffey, Todd
Fisher, Brenda
Delanty-Miller, Laurie
Rymarchyk, Nicole
Kelly, Tracy
Crocenzi, Todd
Bernstein, Eric
Sanborn, Rachel
Urba, Walter J.
Weinberg, Andrew D.
[J]. CANCER RESEARCH, 2013, 73 (24) : 7189 - 7198
[15] Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
D'Agostino, Mattia
Bertamini, Luca
Oliva, Stefania
Boccadoro, Mario
Gay, Francesca
[J]. CANCERS, 2019, 11 (12)
[16] An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line
Deng, ZB
Zhu, W
Lu, CM
Shi, Q
Ju, SG
Ma, HB
Xu, Y
Zhang, XG
[J]. HYBRIDOMA AND HYBRIDOMICS, 2004, 23 (03): : 176 - 182
[17] Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial
Dimopoulos, Meletios A.
Lonial, Sagar
Betts, Keith A.
Chen, Clara
Zichlin, Miriam L.
Brun, Alexander
Signorovitch, James E.
Makenbaeva, Dinara
Mekan, Sabeen
Sy, Oumar
Weisel, Katja
Richardson, Paul G.
[J]. CANCER, 2018, 124 (20) : 4032 - 4043
[18] Synergistic Activity of Belantamab Mafodotin (anti-BCMA immunoconjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines
Eastman, Stephen
Shelton, Christopher
Gupta, Ira
Krueger, Julie
Blackwell, Christina
Bojczuk, Paul M.
[J]. BLOOD, 2019, 134
[19] EORTC, 2020, QLQ30
[20] Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
Farooq, Asim, V
Degli Esposti, Simona
Popat, Rakesh
Thulasi, Praneetha
Lonial, Sagar
Nooka, Ajay K.
Jakubowiak, Andrzej
Sborov, Douglas
Zaugg, Brian E.
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Opalinska, Joanna
Baron, January
Piontek, Trisha
Byrne, Julie
Gupta, Ira
Colby, Kathryn
[J]. OPHTHALMOLOGY AND THERAPY, 2020, 9 (04) : 889 - 911

← 1 2 3 4 5 6 7 8 9 →